FCGR2B and neoplasm: Tumor-specific IgG4 can act as a blocking antibody that competes with inflammatory antibodies such as IgE or IgG1 to bind to antigen or in the form of immune complexes that target the inhibitory receptor FcγRIIb to dampen inflammation.